Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation‐Resistant Frataxin
Proteins: Structure, Function, and Bioinformatics · 2026
DOI: 10.1002/prot.70114 ↗At a glance
Journal article in Proteins: Structure, Function, and Bioinformatics, 2026. Written by Kevser Kübra Kırboğa and 1 co-authors. Institution: Faculty of Engineering, Department of Bioengineering, Bilecik Şeyh Edebali University, Bilecik, TR, Türkiye. Major MEDLINE topics: Iron-Binding Proteins, Protein Engineering. 62 references. Funded by: Friedreich's Ataxia Research Alliance, Scientific and Technological Research Council of Turkey (TÜBİTAK), Health Institutes of Turkey (TÜSEB).
Abstract (original language)
Friedreich's ataxia (FRDA) is a neurodegenerative disorder caused by frataxin (FXN) deficiency, where protein replacement therapy is hampered by the inherent instability and aggregation propensity of wild‐type (WT) FXN. The structural flexibility of Loop‐1 (residues 115–123), a critical region within the acidic ridge, represents a key determinant of protein stability. This study introduces a computational pipeline integrating evolutionary conservation analysis (ConSurf) with diffusion‐based de novo design (RFdiffusion) to redesign both the backbone and sequence of Loop‐1. Through systematic filtration of 1000 ProteinMPNN‐generated variants using aggregation propensity screening (AGGRESCAN) and 450 ns of molecular dynamics (MD) simulations, four lead candidates were identified. Design_188 (EERVGGREI) demonstrated optimal performance with 2.3‐fold improvement in aggregation resistance (Na4vSS: −53.8 vs. −23.5 for WT), superior structural stability (RMSD: 0.486 nm), reduced conformational diversity (62.3% dominant cluster occupancy), and 93% retention of ISCU binding capacity (ΔΔG: +6.4 kcal/mol). Experimental validation through 15 N NMR relaxation analysis confirmed computational predictions, with Design_188 exhibiting uniform backbone rigidification (S 2 = 0.81–0.95) and strong MD‐NMR correlation (Pearson r = 0.675, p = 0.003). SEC‐MALS analysis demonstrated near‐complete monomeric behavior (> 98% monomer content) compared to WT's heterogeneous oligomerization (68% monomer, 32% oligomers), directly confirming the predicted anti‐aggregation properties. K‐means clustering analysis revealed an inverse relationship between conformational heterogeneity and stability, while correlation analysis identified a fundamental trade‐off between aggregation resistance and structural stability ( r = −0.82, p < 0.01). This work establishes a generalizable framework for therapeutic protein engineering where backbone redesign enables conformational ensemble modulation beyond the limitations of sequence optimization alone.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Engineering, Department of Bioengineering, Bilecik Şeyh Edebali University, Bilecik, TR, Türkiye.
- Department of Bioengineering, Süleyman Demirel University, Isparta, TR, Türkiye.
- Süleyman Demirel University, Engineering Faculty, Department of Computer Engineering, Isparta, Türkiye.
ORCID profiles: Kevser Kübra Kırboğa, Ecir Uğur Küçüksille
Funding
- Friedreich's Ataxia Research Alliance
- Scientific and Technological Research Council of Turkey (TÜBİTAK)
- Health Institutes of Turkey (TÜSEB)
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
- Türkiye Sağlık Enstitüleri Başkanlığı
Cite
APA
Kırboğa, K. K., & Küçüksille, E. U. (2026). Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation‐Resistant Frataxin. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.70114
Vancouver
Kırboğa KK, Küçüksille EU. Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation‐Resistant Frataxin. Proteins: Structure, Function, and Bioinformatics. 2026. doi:10.1002/prot.70114
BibTeX
@article{Krboa2026,
author = {Kırboğa, Kevser Kübra and Küçüksille, Ecir Uğur},
title = {Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation‐Resistant Frataxin},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2026},
doi = {10.1002/prot.70114}
}
EUVIMED